Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory depression. Accordingly, there is a longstanding interest in the development: of new opioid analgesics with improved therapeutic profiles. The alkaloids of the Southeast Asian plant Mitragyna speciosa, represented by the prototypical member tnitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological properties. Here we describe the first receptor-level functional characterization of mitragynine and related natural alkaloids at the human mu-, kappa-, and delta-opioid receptors. These results show that mitragynine and the oxidized analogue 7-hydroxymitragynine, ate partial agonists of the human mu-opioid receptor and Competitive antagonists at the kappa- and delta-opioid receptors. We also show that mitragyiline and 7-hydroxymitragyniiie are G -protein -biased agonists of the mu-opioid receptor, which do not recruit beta-arrestin.f011owing receptor activation. 'Therefore, the Mitragyna alkaloid scaffold represents a novel framework for the development of fiinctionally biased opioid modulators, which may exhibit improved therapeutic profiles. Also presented is an enantioselective total synthesis of both,(=--)-mitragynine and its unnatural enantiomer, (+)-mitragynine, employing a proline,catalyzed Mannich Michael reaction sequence as the key transformation. Pharmacological evaluation of (+)-mitragynine revealed its much weaker opioid activity. Likewise, the intermediates and chemical transformations developed in the total synthesis allowed the elucidation of previously unexplored structure activity relationships (SAR) within the Mitragyna scaffold. Molecular docking studies, in combinatiOn with the observed chemical SAR, suggest that Mitragyna alkaloids adopt a binding pose at the ma-opioid receptor that is distinct from that of classical opioids.